MAUDE Adverse Event Report: W. L. GORE & ASSOCIATES, INC. GORE® EXCLUDER® AAA ENDOPROSTHESIS; SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT

Catalog Number	RLT261412
Medical Device Problem Codes	Adverse Event Without Identified Device or Use Problem (2993); Device Endoleak (4074)
Health Effect - Clinical Codes	Aneurysm expansion (4597); Clinical Endoleak (4843)
Date of Event	03/20/2024
Type of Reportable Event	Serious Injury
Additional Manufacturer Narrative
B3: the exact date of event is unknown, therefore, the date of which the explant took place was used as date of event.D10: concomitant medical products: (relevant associated devices used with the device being reported on): gore® excluder®aaa endoprosthesis - contralateral leg (plc201000 / sn 16517679) gore® excluder®aaa endoprosthesis - contralateral leg (plc181000 / sn 16598873) h3 other code, h6 code b15 and b17: the medical device was explanted and the hospital sent the explant to a third party investigator for investigation.Scope and results of the investigation were summarized and a level 1 explant report was provided to gore.Gore explant experts are evaluating the provided report.H6 code b13: requests were emailed to the third party investigator to acquire additional information regarding the disease progression, patient medical details and event dates.The answer is pending.H6 code b14: review of the manufacturing records is ongoing.Per the gore® excluder® aaa endoprosthesis instructions for use (ifu), adverse events that may occur and / or require intervention or additional intraoperative procedure time include, but are not limited to: aneurysm enlargement, endoleak, surgical conversion.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
Event or Problem Description
It was reported to gore (thought a gepromed level 1 macroscopic analysis for explanted grafts 24-041) that a gore® excluder® aaa endoprostheses was implanted on (b)(6) 2018, in order to treat an abdominal aortic aneurysm.On (b)(6) 2024, after about 6 years and 1 month, the endoprosthesis was explanted due to type ii endoleak with enlargement of the aneurysm sac.
Additional Manufacturer Narrative
Updated investigation findings code to c19 - no device problem found.Code c21 is no longer applicable.Updated investigation conclusions code to d15.Code d16 is no longer applicable.As part of our routine quality procedures, each batch of devices undergoes comprehensive quality control testing and inspections prior to release for distribution.Gore reviewed the manufacturing records associated with the reported lot number and verified that all release criteria had been met.The medical device was explanted and the hospital sent the explant to a third party investigator for investigation.Scope and results of the investigation were summarized and a level 1 explant report was provided to gore.Gore explant scientist observations stated the following: the device system was reported to measure 142 mm in length, and consisted of one trunk¿ ipsilateral leg endoprosthesis and two contralateral leg endoprostheses contained within and extending distally from the trunk.The abluminal surface of the device system was covered in moderate, scattered plaques of pink to dark brown biologic material.From distal extremities a and b and extending proximally, the two contralateral leg endoprotheses were covered in thickened, yellow to dark brown biologic material.The lumens of the device systems appeared patent, however no saline-patency test was noted to have been performed, therefore the patency could not be confirmed.Distal extremity b appeared to have been partially transected.From gross images all material disruptions (i.E., material transections), appear to be consistent with cutting by sharp surgical instruments (i.E., scalpel or scissors), likely used during a surgical procedure.Based on the explant scientist¿s review of the gepromed report, no additional analysis is requested.The reason for removal was reported as a type ii endoleak which cannot be confirmed via analysis of the explanted device system.Based on the incident description and the subsequent investigation, no further information was provided to gore, we are unable to determine the cause of this incident and assign a root cause.Updated b5 with new information received from the third party investigator.
Event or Problem Description
It was reported to gore (thought a gepromed level 1 macroscopic analysis for explanted grafts 24-041) that a gore® excluder® aaa endoprostheses was implanted on (b)(6) 2018, in order to treat an abdominal aortic aneurysm (measured 55 mm).On a unknown date in (b)(6) 2018, a type ii endoleak was present on the angioscan.On (b)(6), 2024, after about 6 years and 1 month, the endoprosthesis was explanted due to the type ii endoleak with enlargement of the aneurysm sac (measured 75 mm).

• Brand Name: GORE® EXCLUDER® AAA ENDOPROSTHESIS
• Common Device Name: SYSTEM, ENDOVASCULAR GRAFT, AORTIC ANEURYSM TREATMENT
• Manufacturer (Section D): W. L. GORE & ASSOCIATES, INC.; 1505 n. fourth street; flagstaff AZ 86004
• Manufacturer (Section G): MEDICAL PHOENIX 2 B/P; 32470 n. north valley parkway; phoenix AZ 85085
• Manufacturer Contact: ida simson ; 1505 n. fourth street; flagstaff, AZ 86004 ; 9285263030
• MDR Report Key: 19379593
• Report Number: 3007284313-2024-03258
• Device Sequence Number: 7466485
• Product Code: MIH
• UDI-Device Identifier: 00733132622443
• UDI-Public: 00733132622443
• Combination Product (Y/N): N
• Initial Reporter Country: FR
• PMA/510(K) Number: P020004
• Number of Events Summarized: 1
• Summary Report (Y/N): N
• Device Implanted Year: 2018
• Device Explanted Year: 2024
• Serviced by Third Party (Y/N): N
• Reporter Type: Manufacturer
• Report Source: Other,Foreign
• Initial Reporter Occupation: Physician
• Type of Report: Initial,Followup
• Report Date (Section B): 06/24/2024

1 Device was Involved in the Event

1 Patient was Involved in the Event

• Is this an Adverse Event Report?: Yes
• Is this a Product Problem Report?: No
• Operator of Device: Health Professional
• Device Expiration Date: 12/03/2020
• Device Catalogue Number: RLT261412
• Was Device Available for Evaluation?: No
• Is the Reporter a Health Professional?: Yes
• Type of Report(Section G): Thirty-Day
• Initial Date Received by Manufacturer: 05/21/2024
• Supplement Date Received by Manufacturer: 05/28/2024
• Initial Report FDA Received Date: 05/23/2024
• Supplement Report FDA Received Date: 06/24/2024
• Was Device Evaluated by Manufacturer? (Y/N): Device Not Returned to Manufacturer
• Date Device Manufactured: 12/04/2017
• Is the Device Labeled for Single Use? (Y/N): Yes
• Is This a Single-Use Device that was Reprocessed and Reused on a Patient? (Y/N): No
• Usage of Device: Initial
• Patient Sequence Number: 1
• Concomitant Medical Products and Therapy/Usage Dates: SEE H10
• Outcome Attributed to Adverse Event: Other
• Patient Age: 78 YR
• Patient Sex: Male